RECENT NEWS

Visit the WFH News page to find out more about the events and developments that are making a difference today.

Indonesia-Congress-header

WFH GAP program supports Indonesian NMO’s National Congress

The 6th Indonesian Hemophilia Society National Congress was held virtually on February 26 to 28, 2021, and focused on the theme, “Road to better hemophilia care”. The event was supported in part by the World Federation of Hemophilia (WFH) GAP Program and was attended by over 1,300 participants.

Also available in: Français Español

The 6th Indonesian Hemophilia Society National Congress was held virtually on February 26 to 28, 2021, and focused on the theme, “Road to better hemophilia care”. The event was supported in part by the World Federation of Hemophilia (WFH) GAP Program and was attended by over 1,300 participants.

The Indonesian Hemophilia Society National Congress is held to foster and strengthen collaborative discussion, and support the local bleeding disorders community. February’s event included symposiums, workshops, exhibitions, and sessions—all designed to provide updates on the development of care for bleeding disorders. The event is a national meeting and counts healthcare and multidisciplinary professionals, people with bleeding disorders, researchers, regulators, policy makers and industry representatives among its participants.

The Congress was opened by Novie Chozie, MD, Chairperson of the event; Djajadiman Gatot, MD, Chairman of the Indonesian Hemophilia Society; Cesar Garrido, President of the WFH; and Abdul Kadir, MD, Director General of the Health Service Ministry of Health of Indonesia. Chozie said that the event had allowed the Indonesian Hemophilia Society to open a dialogue with the Director General of Health Service from the Ministry of Health about prophylaxis and national guidelines on hemophilia care and treatment—a development which is sure to have a big impact on the Indonesian bleeding disorders community.

The GAP Program is supported by funding from: Biotest, CSL Behring, Pfizer, Sanofi Genzyme, Sobi and Takeda.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.